Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Parsaclisib (Primary) ; Bendamustine; Ibrutinib; Rituximab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Focus Adverse reactions
  • Acronyms CITADEL-112
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 13 Dec 2022 Results (At data cutoff January 14, 2022) assessing the safety and initial efficacy of parsaclisib in combination with rituximab, bendamustine plus rituximab, or Ibrutinib in patients with previously treated B-cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 27 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2022 Results (Cut off - May 14, 2021, N=50) presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top